ESSENTIAL THROMBOCYTHEMIA, ET
Clinical trials for ESSENTIAL THROMBOCYTHEMIA, ET explained in plain language.
Never miss a new study
Get alerted when new ESSENTIAL THROMBOCYTHEMIA, ET trials appear
Sign up with your email to follow new studies for ESSENTIAL THROMBOCYTHEMIA, ET, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Old arthritis drug could offer new hope for rare blood cancers
Disease control Recruiting nowThis study is testing whether adding a low-dose, inexpensive drug called methotrexate helps people with certain rare blood cancers. Researchers want to see if it safely reduces symptoms like enlarged spleen, fatigue, and abnormal blood cell counts when added to a patient's curren…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA, ET
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Massive study launches to map China's blood disease landscape
Knowledge-focused Recruiting nowThis study aims to gather detailed information on many different blood diseases in China, including cancers like leukemia and lymphoma, and conditions like hemophilia. It will follow 2,300 patients to learn how common these diseases are, what treatments patients receive, how well…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA, ET
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:14 UTC
-
Massive 5,000-Person study launches to map the journey of rare blood cancers
Knowledge-focused Recruiting nowThis is a long-term observational study aiming to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. who have been diagnosed with an MPN for at least five years, collecting information from …
Matched conditions: ESSENTIAL THROMBOCYTHEMIA, ET
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:40 UTC